2:24 PM
Dec 13, 2018
 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc. (South San Francisco, Calif.). Ambys launched in August with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) (see “Ambys Launches With $140M from Series A, Takeda Deal”).

Foghorn Therapeutics Inc. (Cambridge, Mass.) hired Carl Decicco, former head of discovery of Bristol-Myers Squibb Co. (NYSE:BMY), as its first CSO. Decicco has contributed to the approval of over 20 drugs, including cancer drug Sprycel...

Read the full 525 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >